🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis

RecruitingNAAges 20 Years - anyAllMinia University
NCT07394257 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Bacterial keratitis is a potentially sight-threatening corneal infection that is commonly treated with intensive topical antibiotics. Despite appropriate therapy, some cases show inadequate clinical response, particularly when the infection involves the deep corneal stroma. Limited penetration of topical antibiotics into deeper corneal layers may contribute to treatment failure in these recalcitrant cases. Intrastromal antibiotic injection is a targeted drug-delivery approach that allows high local antimicrobial concentrations directly at the site of infection. Moxifloxacin is a broad-spectrum fluoroquinolone with proven efficacy in bacterial keratitis and favorable corneal tissue penetration. However, evidence regarding the clinical benefit and safety of intrastromal moxifloxacin as an adjunctive treatment remains limited. This randomized controlled trial aims to evaluate the efficacy

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * • Age ≥ 18 years * Clinical diagnosis of bacterial keratitis confirmed by corneal scraping and microbiology * Recalcitrant keratitis defined as no significant clinical improvement after 48-72 hours of intensive topical antibiotic therapy * Ability to provide written informed consent Exclusion Criteria * Fungal, viral, or acanthamoeba keratitis * Corneal perforation or impending perforation * Known hypersensitivity to fluoroquinolones * Pregnancy or lactation * Immunocompromised state or current systemic immunosuppressive therapy * Previous intrastromal or intracameral antibiotic injection for the same episode
💊

What it tests

  • Intrastromal moxifloxacin injection plus standard topical moxifloxacin therapy
  • Standard topical moxifloxacin therapy alone
📍

Where

1 site
Mahmoud Ramadan Amer
Minya, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy